Pathology: la/mBC - HR positive - (neo)adjuvant (NA); la/mBC - HR-positive - 2nd line (L2);
| la/mBC - HR positive - (neo)adjuvant (NA) | la/mBC - HR-positive - 2nd line (L2) | ||||
| NEO-ORB (mutant cohort), 2019 | NEO-ORB (wild type cohort), 2019 | SOLAR-1 (patients with PIK3CA mutant status), 2019 | SOLAR-1 (patients without PIK3CA mutant status), 2019 | ||
| alpelisib plus letrozole | 2 | T1 | T1 | ||
| alpelisib plus fulvestrant | 2 | T1 | T1 | ||
| letrozole | 0 | T0 | T0 | ||
| fulvestrant | 0 | T0 | T0 | ||